Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.39 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21990731 | 1.00 | PTPRC (0.39) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL17571008 | 1.00 | PTPRC (0.39) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL31011009 | 0.98 | PTPRC (0.40) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL18411642 | 0.96 | REN (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL22005968 | 0.96 | REN (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL21990730 | 0.96 | REN (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL17570948 | 0.91 | CASP1 (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL19656354 | 0.91 | CASP1 (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL18411799 | 0.90 | RECQL (0.40) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL18913933 | 0.90 | RECQL (0.40) | PTPRCPTPN13RENHDAC8L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981688-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4361128-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3880681-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3380525-B1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN INC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-4163284-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230045079-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-02-09 | — | — | US | disclosed |
| US-9669102-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170050985-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170029514-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2017015496-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017004026-A1 | ANTI-CD 123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160095938-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016036801-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016036794-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981688-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | PTPRC 4416/4885PTPN13 4698/4885REN 4348/4885 |
| US-20230045079-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | PTPRC 4416/4885PTPN13 4698/4885REN 4348/4885 |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | PTPRC 974/4885PTPN13 4074/4885REN 4175/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | PTPRC 3267/4885PTPN13 4549/4885REN 3868/4885 |
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | PTPRC 4297/4885PTPN13 4711/4885REN 4485/4885 |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | PTPRC 3267/4885PTPN13 4549/4885REN 3868/4885 |
| US-20170050985-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | PTPRC 4297/4885PTPN13 4711/4885REN 4485/4885 |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | PTPRC 4297/4885PTPN13 4711/4885REN 4485/4885 |
| US-20170029514-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | PTPRC 92/4885PTPN13 522/4885REN 2953/4885 |
| US-20160095938-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | PTPRC 974/4885PTPN13 4074/4885REN 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.